ECHOSENS
4.3.2020 17:32:10 CET | Business Wire | Press release
Echosens , a high-technology company offering the FibroScan family of products, announces the launch of FibroScan 630 Expert, a high-performance elastography engine that implements newly developed spleen stiffness measurement (SSM by VCTE™) in FibroScan, a non-invasive biomarker that can be used to diagnose and monitor liver health and identified as a valuable diagnostic tool in assessing portal hypertension (PH). The Baveno VI guidelines recognize that elevated liver stiffness measurement by FibroScan can be an effective way to establish the risk of esophageal varices, a common manifestation of PH, increased blood pressure in the veins that enters the liver and is responsible for many of the manifestations of liver cirrhosis. The combination of SSM by VCTE™ in adjunction with Baveno VI criteria allows safely sparing endoscopy in more patients.
“Given the significant increase in potential cases of liver cirrhosis due to non-alcoholic steatohepatitis (NASH) and alcoholic liver disease, there is a critical need for the FibroScan 630 Expert as a cost effective, non-invasive modality for screening and management,” says Professor Massimo Pinzani, M.D., Ph.D., FRCP, Sheila Sherlock chair of hepatology, and director, University College London’s Institute for Liver and Digestive Health. “In cirrhotic patients, spleen stiffness correlates better with Hepatic Venous Pressure Gradient (HVPG ) and presence of high risk esophageal varices than liver stiffness.”
The FibroScan 630 Expert offers improved ergonomics, embedded ultrasound guidance system, intuitive user interface, touchscreen, advanced keyboard and an integrated barcode reader.
In Western countries, alcoholic and viral cirrhosis are the leading causes of PH and esophageal varices, with 30% of patients with compensated cirrhosis and 60-70% of patients with decompensated cirrhosis having gastroesophageal varices at the time of diagnosis. The frequency of gastroesophageal varices directly correlates with the severity of the liver disease from 40% in class A (low risk) to 85% in class C (high risk) in cirrhotic patients.
Laurent Sandrin, chairman and co-founder of Echosens, says, “As liver disease has become an epidemic worldwide, FibroScan 630 Expert serves as an important, non-invasive and cost-effective tool for assessing its severity and prognosis. A dedicated SSM by VCTE™ exam based on a 100 Hz shear wave frequency has been developed to comply with the more elevated stiffness of spleen compared to liver. With liver stiffness measurement (LSM by VCTE™), CAP™ and SSM by VCTE™ as surrogate markers of liver fibrosis, liver steatosis and portal hypertension respectively, the FibroScan 630 provides a comprehensive solution to manage patients with chronic liver diseases including advanced liver disease.”
About Echosens
Echosens is the world’s number one provider of non-invasive medical devices dedicated to assessment of chronic liver diseases.
Echosens pioneered the field of elastography technology by developing FibroScan®, the first device that quantifies liver stiffness non-invasively.
Echosens significantly changed the practice of liver diagnosis with FibroScan®, the unique device using patented and validated VCTE™ for liver fibrosis assessment, and CAP™ for steatosis quantification.
FibroScan® device is recognized worldwide as the reference for non-invasive liver diagnosis with more than 2,000 medical publications and 40 guidelines recommendations.
With a wide-reaching international distribution network, including Europe, spanning France (Paris), Germany, Spain and the United Kingdom, as well as the United States (Waltham) and China (Shanghai, Shenzhen and Beijing), Echosens has made FibroScan® available in over 80 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200304005612/en/
Link:
Social Media:
https://www.facebook.com/EchosensNorthAmerica/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom